WHO welcomes data on COVID-19 in China, meeting with Minister

Earlier today, WHO Director-General Dr Tedros Adhanom Ghebreyesus spoke with Minister Ma Xiaowei, director of China’s National Health Commission, about the COVID-19 situation in the country. WHO appreciates this meeting, as well as the public release of information on the overall situation.  

Chinese officials provided information to WHO and in a press conference on a range of topics, including outpatient clinics, hospitalizations, patients requiring emergency treatment and critical care, and hospital deaths related to COVID-19 infection.   

WHO is analysing this information, which covers early December 2022 to 12 January 2023, and allows for a better understanding of the epidemiological situation and the impact of this wave in China. WHO requested that this type of detailed information continue to be shared with us and the public. WHO notes the efforts by Chinese authorities to scale up clinical care for its population at all levels, including in critical care. 

The overall epidemiology – reflecting a rapid and intense wave of disease caused by known sub-variants of Omicron with higher clinical impact on older people and those with underlying conditions – is similar to waves of infection experienced by other countries, as is the increased pressure on health services. The reported data indicate a decline in case numbers, hospitalizations, and those requiring critical care. WHO has requested a more detailed breakdown of data by province over time.   

WHO announces plans to establish a TB Vaccine Accelerator council

The adverse impact of the COVID-19 pandemic on tuberculosis (TB) services has brought the urgency of vaccine development efforts into sharp focus. Speaking earlier today at a high-level panel on TB at the World Economic Forum, Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, announced plans to establish a new TB Vaccine Accelerator Council.

The Council will facilitate the licensing and use of effective novel TB vaccines catalysing high-level alignment between funders, global agencies, governments and end users in identifying and overcoming barriers to TB vaccine development.

“One of the most important lessons from the response to the COVID-19 pandemic is that innovative  health interventions can be delivered fast if they are prioritized politically and financed adequately”, said Dr Tedros Adhanom Ghebreyesus. “The challenges presented by TB and COVID-19 are different, but the ingredients that accelerate science, research and innovation are the same: urgent, up-front public investment; support from philanthropy; and engagement of the private sector and communities. We believe the TB field will benefit from similar high-level coordination.”

Address

9066 Green Lake Drive Chevy Chase, MD 20815

Whatsapp Us

+91 87885 41706

contact@vvsexim.com

Download the app now!

VVS Exim is proud of being a best Merchant Exporter in India with high-quality medicines, supplements, healthcare product.

+91 95452 74105

vvsexim0054@gmail.com

GST No. 27AAUHP0112N1ZT
Our Payment : All Payments Accepted with Bank Account only
Copyright © 2024 | VVS Exim – Merchant Exporter | All Rights Reserved.
Reach us on WhatsApp
1
X
Add to cart